Bicycle Therapeutics Plc (BCYC) Stock Price, Financials & Summary

Price chart

Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21

Key dataOct 21, 2026

Open$3.62

From 52W high−59.25%

Volume406302.00

Market cap$249.87M

P/E (TTM)—

P/S (TTM)4.1x

Div yield—

Key dataOct 21, 2026

Open

$3.62

From 52W high

−59.25%

Volume

406302.00

Market cap

$249.87M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.3x

P/E (TTM)

—

RSI (14)

47.8

MomentumView details →

1D Return

−0.83%

YTD Return

−48.42%

SummaryUpdated Jun 1, 2026

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Cambridge, United Kingdom. The company went public on NASDAQ in May 2019, raising capital to advance its innovative bicycle peptide drug platform. Bicycle Therapeutics specializes in developing a novel class of medicines called bicycle peptides, which are designed to address diseases that are poorly served by existing therapeutic options, particularly in oncology and other therapeutic areas.

Ask drillr about Bicycle Therapeutics Plc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

1.3x

EV/Sales

−4.0x

P/S (TTM)

4.1x

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−311.11%

EBITDA Margin

−299.32%

ROE (TTM)

−37.32%

ROA (TTM)

−31.39%

Asset Turnover

0.10x

GrowthView details →

Revenue YoY

+217.44%

EPS YoY

+22.00%

FCF YoY

+2.39%

Revenue CAGR 3Y

+71.21%

EPS CAGR 3Y

−8.59%

EBITDA YoY

+30.83%

MomentumView details →

1D Return

−0.83%

YTD Return

−48.42%

1Y Return

−53.65%

RSI (14)

47.8

vs 50D SMA

−5.94%

vs 200D SMA

−21.74%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

12.08x

Quick Ratio

12.08x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.72

EPS Surprise

−27.59%

Beats (12Q)

6/12

Next Q EPS Est

−$0.44

Avg Surprise (4Q)

4.55%

Rev Surprise

−85.10%

Financials snapshotView financials →

Revenue (TTM)

61.20M

Net Income (TTM)

−190.41M

Op. CF (TTM)

−205.72M

Next earningsOct 29, 2026 →

Latest newsMore news →

Charles Swanton resigned as Class II director of Bicycle Therapeutics PLC's Board of Directors, effective August 18, 2026.63d ago

Bicycle Therapeutics PLC reported financial results for the second quarter of 2026, with collaboration revenue of $629,000 and a net loss of $50.3 million.84d ago

Similar companies

Larimar Therapeutics, Inc.LRMR Fate Therapeutics, Inc.FATE BioAge Labs, Inc.BIOA Lexeo Therapeutics, Inc. Common StockLXEO AC Immune S.A.ACIU Palisade Bio, Inc.PALI Find similar companies →

Latest newsMore news →

Charles Swanton resigned as Class II director of Bicycle Therapeutics PLC's Board of Directors, effective August 18, 2026.63d ago Bicycle Therapeutics PLC reported financial results for the second quarter of 2026, with collaboration revenue of $629,000 and a net loss of $50.3 million.84d ago